关于知识产权 知识产权培训 树立尊重知识产权的风尚 知识产权外联 部门知识产权 知识产权和热点议题 特定领域知识产权 专利和技术信息 商标信息 工业品外观设计信息 地理标志信息 植物品种信息(UPOV) 知识产权法律、条约和判决 知识产权资源 知识产权报告 专利保护 商标保护 工业品外观设计保护 地理标志保护 植物品种保护(UPOV) 知识产权争议解决 知识产权局业务解决方案 知识产权服务缴费 谈判与决策 发展合作 创新支持 公私伙伴关系 人工智能工具和服务 组织简介 与产权组织合作 问责制 专利 商标 工业品外观设计 地理标志 版权 商业秘密 WIPO学院 讲习班和研讨会 知识产权执法 WIPO ALERT 宣传 世界知识产权日 WIPO杂志 案例研究和成功故事 知识产权新闻 产权组织奖 企业 高校 土著人民 司法机构 遗传资源、传统知识和传统文化表现形式 经济学 金融 无形资产 性别平等 全球卫生 气候变化 竞争政策 可持续发展目标 前沿技术 移动应用 体育 旅游 PATENTSCOPE 专利分析 国际专利分类 ARDI - 研究促进创新 ASPI - 专业化专利信息 全球品牌数据库 马德里监视器 Article 6ter Express数据库 尼斯分类 维也纳分类 全球外观设计数据库 国际外观设计公报 Hague Express数据库 洛迦诺分类 Lisbon Express数据库 全球品牌数据库地理标志信息 PLUTO植物品种数据库 GENIE数据库 产权组织管理的条约 WIPO Lex - 知识产权法律、条约和判决 产权组织标准 知识产权统计 WIPO Pearl(术语) 产权组织出版物 国家知识产权概况 产权组织知识中心 产权组织技术趋势 全球创新指数 世界知识产权报告 PCT - 国际专利体系 ePCT 布达佩斯 - 国际微生物保藏体系 马德里 - 国际商标体系 eMadrid 第六条之三(徽章、旗帜、国徽) 海牙 - 国际外观设计体系 eHague 里斯本 - 国际地理标志体系 eLisbon UPOV PRISMA UPOV e-PVP Administration UPOV e-PVP DUS Exchange 调解 仲裁 专家裁决 域名争议 检索和审查集中式接入(CASE) 数字查询服务(DAS) WIPO Pay 产权组织往来账户 产权组织各大会 常设委员会 会议日历 WIPO Webcast 产权组织正式文件 发展议程 技术援助 知识产权培训机构 COVID-19支持 国家知识产权战略 政策和立法咨询 合作枢纽 技术与创新支持中心(TISC) 技术转移 发明人援助计划(IAP) WIPO GREEN 产权组织的PAT-INFORMED 无障碍图书联合会 产权组织服务创作者 WIPO Translate 语音转文字 分类助手 成员国 观察员 总干事 部门活动 驻外办事处 职位空缺 采购 成果和预算 财务报告 监督
Arabic English Spanish French Russian Chinese
法律 条约 判决 按管辖区浏览

2006年9月30日,关于药品注册记录数据安全的实施细则, 越南

返回
WIPO Lex中的最新版本
详情 详情 版本年份 2006 日期 发布: 2006年9月30日 文本类型 实施规则/实施细则 主题 未披露的信息(商业秘密) 越南根据TRIPS第63条第2款发给世贸组织的通知中称:
“本决定公布了适用于药品注册(对申请上市销售批准过程中提交数据的保护)中数据保护的实施细则。”

可用资料

主要文本 相关文本
主要文本 主要文本 英语 Regulation of September 30, 2006, on Data Security of Drug Registration Records        
 VN019: Undisclosed Information (Drugs Registration Records), Regulation, 30/09/2006

REGULATION ON DATA SECURITY OF DRUG REGISTRATION RECORDS (Promulgated together with the Health Minister’s Decision No. 30/2006/QD-BYT of September 30, 2006)

Chapter I

GENERAL PROVISIONS

Article 1.- Scope of regulation and subjects of application

1. Scope of regulation: This Regulation provides the order and procedures related to the security of data of drug registration records.

2. Subjects of application: This Regulation applies to domestic and foreign organizations and individuals that carry out drug registration procedures in Vietnam and to concerned agencies in charge of state management of pharmacy.

Article 2.- Interpretation of terms

In this Regulation, the terms below are construed as follows:

1. Drug means a substance or a mixture of substances for human use for the purposes of disease prevention, treatment or diagnosis or rehabilitation of human physical functions, including finished drugs, drug materials, vaccines and medical biologicals, except functional foodstuff.

2. Pharmaceutical substance (also referred to as active ingredient) means a substance or a mixture of substances having treatment active-ingredients which are used in drug manufacture.

3. New drug means a drug containing a new pharmaceutical substance or drug with a new combination of circulated pharmaceutical substances.

4. Clinical drug test means a scientific research into drugs on humans in a systematic manner with a view to verifying clinical efficiency, identifying and discovering harmful effects of the researched products; the ability of such products to absorb, distribute, transform or discharge, aiming to determine the safety and effectiveness of drugs.

5. Additional indication, formula or preparation form means a new indication, new formula or new preparation form of a new drug which has been granted a circulation registration number.

6. Business secret means information received from financial investment or intellectual activities which has not been revealed and can be used in business activities.

7. Data security means the application of necessary measures to ensure that data are neither used for unhealthy commercial purposes nor revealed, unless when the revelation is necessary for the protection of people.

Article 3.- Types of data to be secured

1. Test results related to toxicity and clinical drug test data of new drugs which have never been publicized or revealed.

2. Other data (except additional indications, formulas and preparation forms) which meet the conditions specified in Article 4 of this Regulation.

2 Article 4.- Conditions for data to be secured

Data to be secured must fully meet the following conditions:

1. Being business secrets.

2. Being results of investment of significant efforts.

3. Being supplied by drug-registering establishments under current regulations on drug registration.

4. Being requested to be secured by drug-registering establishments under the provisions of Article 5 of this Regulation.

Article 5.- Required documents for data security consideration

1. Required documents include:

a/ An application for enforcement of data security (made according to a set form);

b/ A document proving that data which need be secured fully meet the conditions specified in Clause 1, Article 4 of this Regulation.

c/ A document proving that data which need be secured are under lawful ownership of the drug- registering establishment which requests the enforcement of data security.

2. The application for enforcement of data security and proof documents specified in Clause 1 of this Article constitute part of a drug registration dossier and must be submitted together with the dossier. Applications and documents submitted after drug registration dossiers shall not be considered.

Article 6.- Forms of applications and documents related to data security enforcement request

1. An application for enforcement of data security and enclosed documents must be made in Vietnamese or English, signed and stamped for certification by the drug-registering establishment on every page of those documents.

2. Legal documents (diplomas, certificates, etc.) must be originals or copies notarized in Vietnam. Diplomas and certificates which are issued, notarized or authenticated by foreign agencies or organizations must be legalized by consular offices and translated into Vietnamese. The translations must be notarized in accordance with Vietnamese law.

3. Parts of a dossier which contain data to be secured must be sealed and appended with a confidentiality stamp of the drug-registering establishment.

Chapter II

PROCEDURES FOR SUBMISSION AND RECEIPT OF DRUG REGISTRATION DOSSIERS CONTAINING DATA TO BE SECURED

Article 7.- Submission of dossiers

1. A drug registration dossier containing data which need be secured and relevant proof documents shall be submitted directly at the drug circulation-licensing agency or at the place of receipt of dossiers designated by the drug circulation-licensing agency, or shall be sent by registered mail.

3 2. If, at the time the drug registration dossier is being submitted (or arriving at the drug circulation- licensing agency), the parts of data which need be secured no longer have confidentiality signs or intact seals, the drug circulation-licensing agency shall not be responsible for data security.

Article 8.- Receipt of dossiers

Upon receiving a drug registration dossier containing data which need be secured, the drug circulation-licensing agency shall:

1. Inspect the intactness of the dossier and its confidentiality seal.

2. Check documents in the dossier against those listed in the application for enforcement of data security.

3. Append a stamp on the application and all enclosed documents, certifying the date of receipt of the dossier; and write down necessary information in the dossier receipt book.

4. Temporarily keep data which need be secured according to current regulations until it officially accepts or rejects the application for enforcement of data security.

Chapter III

RESPONSIBILITIES OF THE DRUG CIRCULATION-LICENSING AGENCY

Article 9.- Consideration of and reply to a data security enforcement request

1. Within six months after receiving a drug registration dossier containing data which need be secured, the drug circulation-licensing agency shall evaluate the application for enforcement of data security and relevant documents required in Articles 3, 4, 5 and 6 of this Regulation and notify in writing the drug-registering establishment of its acceptance or rejection of the data security enforcement request.

2. If rejecting a data security enforcement request, the drug circulation-licensing agency shall clearly state the reasons therefor.

Article 10.- Security enforcement and duration

1. For data to be secured, the drug circulation-licensing agency shall take necessary security measures as stipulated in Clause 1, Article 128 of the Intellectual Property Law until those data no longer meet the conditions specified in Article 4 of this Regulation.

2. Except the case defined at Point d, Clause 2, Article 125 of the Intellectual Property Law, within 5 years after the drugs for which the drug registration dossier containing confidential is submitted to the drug circulation-licensing agency are granted circulation permits, the drug circulation-licensing agency may not license any drug-registering establishments which submit later dossiers with the same confidential data without consent of the person who has submitted those data.

Article 11.- Processing of data after security duration

At the end of the security duration stipulated in Article 10 of this Regulation, the submitted data shall be archived by the drug circulation-licensing agency like data which need not be secured.

4 Chapter IV

HANDLING OF VIOLATIONS

Article 12.- Handling of violations

Organizations or individuals that violate the provisions of this Regulation shall, depending on the severity of their violations, be disciplined, administratively sanctioned or examined for penal liability in accordance with law.

Minister of Health TRAN THI TRUNG CHIEN


立法 由以下文本公布 (1 文本) 由以下文本公布 (1 文本)
无可用数据。

WIPO Lex编号 VN019